Iomeprol in CT of the brain: multicentre phase II study

The aim of the study was to assess the effectiveness and safety of iomeprol (300 mg I/ml) in CT of the brain. Thirty-one patients were enrolled according to strict inclusion and exclusion criteria necessary for a phase II study. The efficacy was judged to be good in 10 patients and excellent in 21. None of the patients showed clinically significant changes in vital parameters, ECG and EEG tracings or laboratory tests. Among the 31 patients there were no subjective reactions and only 1 patient complained of a side-effect. Taking into account the results of this multicentre trial we can conclude that iomeprol is a good contrast medium with excellent local and systemic tolerability.